Your SlideShare is downloading. ×
 Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report
 Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report
 Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report
 Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report
 Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report

97

Published on

Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report @ http://www.researchmoz.us/respiratory-tract-infections-pipeline-review-h2-2013-report.html

Respiratory Tract Infections - Pipeline Review, H2 2013::Industry Analysis Report @ http://www.researchmoz.us/respiratory-tract-infections-pipeline-review-h2-2013-report.html

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
97
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Respiratory Tract Infections - Pipeline Review, H2 2013 Global Markets Directs, 'Respiratory Tract Infections Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Respiratory Tract Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Respiratory Tract Infections. A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. table Of Contents table Of Contents 2 list Of Tables 5 list Of Figures 5 introduction 6 global Markets Direct Report Coverage 6 respiratory Tract Infections Overview 7 therapeutics Development 8 Respiratory Tract Infections - Pipeline Review, H2 2013
  • 2. an Overview Of Pipeline Products For Respiratory Tract Infections 8 respiratory Tract Infections Therapeutics Under Development By Companies 10 late Stage Products 12 comparative Analysis 12 mid Clinical Stage Products 13 comparative Analysis 13 early Clinical Stage Products 14 comparative Analysis 14 discovery And Pre-clinical Stage Products 15 comparative Analysis 15 respiratory Tract Infections Therapeutics - Products Under Development By Companies 16 companies Involved In Respiratory Tract Infections Therapeutics Development 17 johnson & Johnson 17 shionogi & Co., Ltd. 18 glaxosmithkline Plc 19 daiichi Sankyo Company, Ltd 20 taisho Pharmaceutical Co., Ltd. 21 nanotherapeutics, Inc. 22 cubist Pharmaceuticals, Inc. 23 nippon Shinyaku Co., Ltd. 24 dongwha Pharm Co., Ltd. 25 novabiotics Ltd 26 ibio, Inc. 27 afexa Life Sciences Inc. 28 respiratory Tract Infections - Therapeutics Assessment 29 assessment By Monotherapy Products 29 assessment By Route Of Administration 30 assessment By Molecule Type 32 drug Profiles 34 gentamicin Sulfate - Drug Profile 34 product Description 34 mechanism Of Action 34 r&d Progress 34 cidofovir - Drug Profile 35 product Description 35 mechanism Of Action 35 r&d Progress 35 cvt-e002 - Drug Profile 36 product Description 36 mechanism Of Action 36 r&d Progress 36 prulifloxacin - Drug Profile 38 product Description 38 Respiratory Tract Infections - Pipeline Review, H2 2013
  • 3. mechanism Of Action 38 r&d Progress 38 zabofloxacin - Drug Profile 40 product Description 40 mechanism Of Action 40 r&d Progress 40 anthrax Monoclonal Antibody - Drug Profile 42 product Description 42 mechanism Of Action 42 r&d Progress 42 gsk-2140944 - Drug Profile 43 product Description 43 mechanism Of Action 43 r&d Progress 43 s-649266 - Drug Profile 44 product Description 44 mechanism Of Action 44 r&d Progress 44 novarifyn - Drug Profile 45 product Description 45 mechanism Of Action 45 r&d Progress 45 pl-401 - Drug Profile 46 product Description 46 mechanism Of Action 46 r&d Progress 46 pl-402 - Drug Profile 47 product Description 47 mechanism Of Action 47 r&d Progress 47 antibacterial Drug - Drug Profile 48 product Description 48 mechanism Of Action 48 r&d Progress 48 compound-g1 - Drug Profile 49 product Description 49 mechanism Of Action 49 r&d Progress 49 compound-2a - Drug Profile 50 product Description 50 mechanism Of Action 50 r&d Progress 50 pam2cys - Drug Profile 51 Respiratory Tract Infections - Pipeline Review, H2 2013
  • 4. product Description 51 mechanism Of Action 51 r&d Progress 51 drug For Respiratory Tract Infections - Drug Profile 52 product Description 52 mechanism Of Action 52 r&d Progress 52 respiratory Tract Infections Therapeutics - Drug Profile Updates 53 respiratory Tract Infections Therapeutics - Discontinued Products 55 respiratory Tract Infections Therapeutics - Dormant Products 56 respiratory Tract Infections - Product Development Milestones 57 featured News & Press Releases 57 apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 57 jan 10, 2011: Mpex Initiates Aeroquin Phase Iii Trial For Treatment Of Chronic Bacterial Infections In Cystic Fibrosis Patients 57 oct 21, 2010: Transave Announces ’s Arikace Demonstrates Sustained Benefit In Multiple Studies Of Pseudomonas Lung Infections In Cystic Fibrosis Patients 58 oct 04, 2010: The Conclusion Of A License Agreement For An Antibacterial Agent ‘prulifloxacin’ 59 aug 24, 2009: Nanotherapeutics Awarded $30.9 Million Niaid Contract To Develop Inhaled Antiviral For Prophylaxis And Treatment Of Smallpox 59 mar 03, 2009: The Conclusion Of A License Agreement For An Antibacterial Agent ‘prulifloxacin’ In China 60 oct 27, 2004: Launch Of Nippon Shinyaku's Quinolone Antibacterial Agent In Italy 60 jun 28, 2004: The Conclusion Of Licensing Agreement For An Antibacterial Agent 'prulifloxacin' In The U.s. 60 mar 23, 2004: Impax Receives Final Fda Approval For Generic Version Of Declomycin; Fifth Anda Approval In 2004 61 appendix 62 methodology 62 coverage 62 secondary Research 62 primary Research 62 expert Panel Validation 62 contact Us 63 disclaimer 63 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as Respiratory Tract Infections - Pipeline Review, H2 2013
  • 5. publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Respiratory Tract Infections - Pipeline Review, H2 2013

×